Synapse - Works

Results (988)

Risk of arterial and venous thrombosis in 11,155 patients with myeloproliferative neoplasms and 44,620 matched controls; a population-based study

Meeting Abstract

Hultcrantz, M.; Andersson, T. M. L.; Landgren, O.; Derolf, A. R.; Dickman, P. W.; Bjorkholm, M.; Kristinsson, S. Y.
Blood (2014)

Fulltext@MSK | Save

Greater total dose and duration of treatment with bortezomib are associated with higher incidence of chalazion and other ocular side effects

Meeting Abstract

Ganesh, K.; Batlevi, C.; Zhang, Z. G.; Hassoun, H.; Lendvai, N.; Landau, H.; Moskowitz, C. H.; Caron, P.; Motzer, R.; Giralt, S. A.; more...
Blood (2014)

Fulltext@MSK | Save

Recombinant (rec) MAGE-A3 protein immunotherapy and peripheral blood lymphocyte (PBL) reconstitution induce strong antigen-specific humoral and cellular immune responses in patients undergoing autologous stem cell transplantation (ASCT) for consolidation of multiple myeloma (MM)

Meeting Abstract

Cohen, A. D.; Lendvai, N.; Gnjatic, S.; Jungbluth, A. A.; Bertolini, S.; Pan, L.; Venhaus, R.; Tsakos, I.; Garcia, K.; Thibodeau, L.; more...
Blood (2014)

Fulltext@MSK | Save

Analysis of VDT-PACE utilization in multiple myeloma patients treated at MSKCC for relapsed disease or cytoreduction and stem cell mobilization after initial induction therapy

Meeting Abstract

Beyer, K.; Rosner, S.; Woo, K. M.; Devlin, S. M.; Landau, H.; Hassoun, H.; Lendvai, N.; Chung, D. J.; Adel, N. G.; Puto, M.; more...
Blood (2014)

Fulltext@MSK | Save

Nivolumab in patients with relapsed or refractory Hodgkin lymphoma - Preliminary safety, efficacy and biomarker results of a phase I study

Meeting Abstract

Armand, P.; Ansell, S. M.; Lesokhin, A. M.; Halwani, A.; Millenson, M. M.; Schuster, S. J.; Timmerman, J.; Borrello, I.; Gutierrez, M.; Scott, E. C.; more...
Blood (2014)

Fulltext@MSK | Save

Upfront plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for autologous stem cell mobilization in multiple myeloma patients: An update on cost analysis study at Memorial Sloan Kettering Cancer Center

Meeting Abstract

Afifi, S.; Adel, N. G.; Duck, E.; Devlin, S. M.; Landau, H.; Lendvai, N.; Lesokhin, A. M.; Chung, D. J.; Landgren, O.; Giralt, S. A.; more...
Blood (2014)

Fulltext@MSK | Save

Survival, response duration, and activity by BRAF mutation (MT) status in a phase 1 trial of nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL)

Meeting Abstract

Kluger, H.; Sznol, M.; Callahan, M.; Postow, M.; Gordon, R.; Segal, N. H.; Rizvi, N.; Lesokhin, A.; Atkins, M. B.; Kirkwood, J.; more...
Annals of Oncology (2014)

Fulltext@MSK | Save

The road to treating smoldering multiple myeloma

Conference Paper

Korde, N.; Mailankody, S.; Landgren, O.
Elsevier Inc. (2014)

Fulltext@MSK | Save

Successful perioperative use of prothrombin complex concentrate in the treatment of acquired factor X deficiency in the setting of systemic light-chain (AL) amyloidosis

Journal Article

Litvak, A.; Kumar, A.; Wong, R. J.; Smith, L.; Hassoun, H.; Soff, G.
American Journal of Hematology (2014)

Fulltext@MSK | Save

Elevated risk of venous but not arterial thrombosis in Waldenström macroglobulinemia/lymphoplasmacytic lymphoma

Journal Article

Hultcrantz, M.; Pfeiffer, R. M.; Björkholm, M.; Goldin, L. R.; Turesson, I.; Schulman, S.; Landgren, O.; Kristinsson, S. Y.
Journal of Thrombosis and Haemostasis (2014)

Fulltext@MSK | Save